Prasugrel: To Be (Approved) Or Not To Be
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.
You may also be interested in...
Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
Prasugrel Delay Shifts Focus To Possible August Advisory Committee
FDA extends user fee date for the novel anti-platelet drug to Sept. 26.